Poseida Therapeutics
@PoseidaThera
Followers
4K
Following
225
Media
362
Statuses
699
Poseida was acquired by Roche in early 2025 and is now part of the Roche Group.
San Diego, CA
Joined May 2017
Today we completed our merger with @Roche, making Poseida a wholly owned subsidiary within Roche’s Pharmaceutical Division. Together we’ll continue to advance innovative therapies with the #capacitytocure. Learn more:
0
1
6
Reflecting on the past year, we are grateful for the numerous achievements and milestones we've reached together. We wish all a happy and healthy New Year. Here's to a bright future ahead!
0
0
0
We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24!.
0
1
4
Learn more about our CEO, Kristin Yarema’s, Ph.D., career in #biotech and her vision for the future of #allogeneic cell therapy and non-viral genetic medicines. All this and more in @Biotech2050Pod latest podcast out now: #CapacitytoCure #celltherapy.
0
0
3
Tune into @CGT_Live's latest interview with Bhagirathbhai Dholaria, MD, discussing Poseida’s #IMS2024 data on P-BCMA-ALLO1 in multiple myeloma: #CapacitytoCure #celltherapy.
cgtlive.com
The associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center discussed interim data from the phase 1/1b clinical trial evaluating...
0
0
2
Our CEO, Kirstin Yarema, Ph.D., will provide a corporate presentation at Stifel’s 2024 Healthcare Conference on Monday, November 18. The presentation will be webcast live on our website at with a replay available shortly thereafter. #CapacitytoCure
0
0
3
Poseida is going live at 10 am ET. Join our exciting #celltherapy R&D Day, where we’ll share the latest on our clinical & early-stage cell therapy programs targeting #oncology and #autoimmune disease: More details in today’s news:
0
0
4
We are so proud to be recognized as a @biospace Best Place to Work for the second year in a row! A big thanks to our dedicated, passionate, and patient-centric team for all their hard work and earning this recognition. More here: #CapacitytoCure
0
1
2
Honoring the brave men and women who have served in the military today and every day. Your courage, sacrifice, and commitment to our nation inspires us all. Thank you for your service. #PoseidaProud #HonoringHeroes #CapacitytoCure
0
0
0
Today we announced our third quarter updates and #financial results. The latest #news is available here: $PSTX #CapacitytoCure #celltherapy #geneticmedicines
0
0
2
Join our 11/14 virtual event showcasing cutting-edge innovations across our clinical and early-stage allogeneic #celltherapy programs targeting #oncology and #autoimmune diseases. Don’t miss this opportunity!. Register today: #CapacitytoCure $PSTX
0
0
1
#SITC24 abstracts are now live ahead of our poster presentation on November 9 in Houston. Plus, Poseida will present three poster presentations at #ASH24, happening in San Diego from December 7-10. All details here: #CapacitytoCure #celltherapy
0
0
2
At Biocom California's San Diego Life Science CEO Summit, our Executive Chairman, Mark Gergen, joins industry leaders for a panel on collaborations with pharma. If attending, please join the discussion on Thursday, November 7 at 10 AM PT. Agenda here:
0
0
0
Today we announced preclinical #data, to be presented at #ACAAI24, on the potential of P-KLKB1-101 to provide a differentiated treatment option for #HAE with encouraging early tolerability, safety and efficacy results. Details here: #CapacitytoCure #HAE
0
0
2
We're thrilled to announce @Roche has expanded our collaboration with the nomination of a new #allogeneic dual CAR-T therapy targeting antigens expressed in hematologic malignancies, including #multiplemyeloma. More on this latest collaboration milestone:
0
0
2
Did you know 1 in 8 women in the U.S. will face a #breastcancer diagnosis in her lifetime? It’s crucial we stand ready to support them. This #BreastCancerAwareness Month, let’s keep patients and families we serve at the forefront of our mission. #celltherapy #geneticmedicines
0
0
1
We are excited to announce team members from Poseida will be presenting a poster demonstrating the engineering power of our non-viral #allogeneic technology at #SITC24 in Houston. Presentation info. available now: #CapacitytoCure #celltherapy @sitcancer
0
1
4
Want firsthand insight into our clinical trial for P-BCMA-ALLO1? Read this article from @AJMC_Journal for a Q&A with Bhagirathbhai Dholaria, M.D., on our investigational CAR-T therapy in #multiplemyeloma for more: #CapacitytoCure #celltherapy.
ajmc.com
Attendees at the International Myeloma Society 21st Annual Meeting & Exposition got an early look at data for an investigational allogeneic chimeric antigen receptor (CAR) T-cell product from healthy...
0
0
1
We are excited to share that our CEO, Kristin Yarema, Ph.D., has been recognized on the @PharmaVoice 100 list as a pioneer in cell and gene therapy. More on her #recognition, her #career to date, and the full list of inspiring industry leaders out now:.
0
1
1